Menu
Search
|

Menu

Close
X

Intellipharmaceutics International Inc IPCI.OQ (NASDAQ Stock Exchange Capital Market)

0.69 USD
-0.08 (-10.38%)
As of Feb 17
chart
Previous Close 0.77
Open 0.76
Volume 73,565
3m Avg Volume 56,277
Today’s High 0.76
Today’s Low 0.66
52 Week High 2.91
52 Week Low 0.66
Shares Outstanding (mil) 31.02
Market Capitalization (mil) 34.07
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
4
FY16
2
FY15
4
EPS (USD)
FY17
-0.209
FY16
-0.376
FY15
-0.310
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
7.81
5.77
Price to Book (MRQ)
vs sector
42.05
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
157.71
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-1,305.65
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Isa Odidi
Chairman of the Board, Chief Executive Officer, Since 2009
Salary: $581,965.00
Bonus: $182,299.00
Amina Odidi
President, Chief Operating Officer, Director, Since 2010
Salary: $581,965.00
Bonus: $182,299.00
Andrew Patient
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
John Allport
Vice President - Legal Affairs and Licensing, Secretary, Director, Since 2009
Salary: $132,167.00
Bonus: $91,149.00
Patrick Yat
Vice President - Pharmaceutical Analysis and Chemistry, Since 2009
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

30 Worcester Rd
ETOBICOKE   ON   M9W 5X2

Phone: +1416.7983001
Site:

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.

SPONSORED STORIES